Skip directly to local search Skip directly to A to Z list Skip directly to navigation Skip directly to site content Skip directly to page options
CDC Home

Volume 15, Number 10—October 2009

Research

Nontuberculous Mycobacteria Infections and Anti–Tumor Necrosis Factor-α Therapy

Kevin L. WinthropComments to Author , Eric Chang, Shellie Yamashita, Michael F. Iademarco, and Philip A. LoBue
Author affiliations: Oregon Health and Sciences University, Portland, Oregon, USA (K.L. Winthrop, E. Chang, S. Yamashita); US Public Health Service, Washington, DC, USA (M.F. Iademarco); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (P.A. LoBue)

Main Article

Figure 1

Case reports of nontuberculous mycobacteria in patients using antitumor necrosis factor-α (TNF-α) therapy, US Food and Drug Administration MedWatch database, 1999–2006. Cases are reported by each full year of data reporting for each anti-TNF agent. Reported cases for all agents were most numerous in 2005. INF, infliximab; ADA, adalimumab; ETN, etanercept.

Figure 1. Case reports of nontuberculous mycobacteria in patients using antitumor necrosis factor-α (TNF-α) therapy, US Food and Drug Administration MedWatch database, 1999–2006. Cases are reported by each full year of data reporting for each anti-TNF agent. Reported cases for all agents were most numerous in 2005. INF, infliximab; ADA, adalimumab; ETN, etanercept.

Main Article

Top of Page

 

Past Issues

Select a Past Issue:

Art in Science - Selections from Emerging Infectious Diseases
Now available for order



CDC 24/7 – Saving Lives, Protecting People, Saving Money. Learn More About How CDC Works For You…

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO